Evidence map›Paper›PMID 39127976›Full record

ArticleBulletin of experimental biology and medicine2024

Antigenotoxic Activity of Polyphenolic Composition BP-C2 in Mouse Germ Cells In Vivo.

A K Zhanataev, E A Anisina, A D Malikova, K L Pligina, S E Pigarev, E I Fedoros, A D Durnev, V N Anisimov

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A K ZhanataevFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia. zhanataev_ak@academpharm.ru.
E A AnisinaFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.
A D MalikovaFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.
K L PliginaFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.
S E PigarevN. N. Pet-rov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia.
E I FedorosN. N. Pet-rov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia.
A D DurnevFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.
V N AnisimovN. N. Pet-rov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In vivo antigenotoxic activity of BP-C2 composition (at doses of 60, 80, and 120 mg/kg) based on polyphenolic compounds derived from hydrolyzed lignin was evaluated in mouse germ cells. The BP-C2 composition dose-dependently reduced the aneugenic activity of topoisomerase II inhibitor etoposide in mouse oocytes without affecting the clastogenic activity of the genotoxicant. In mouse testicular cells, the BP-C2 composition reduced the DNA-damaging activity of the pro-oxidant genotoxicant dioxidine, but not etoposide. The cytoprotective activity of BP-C2 composition was revealed in relation to etoposide-induced cytotoxicity.

Indexed as

EtoposidePolyphenolsAnimalsAntimutagenic AgentsDNA DamageFemaleMaleMiceOocytesSpermatozoaTestisTopoisomerase II InhibitorsAntimutagenic AgentsEtoposidePolyphenolsTopoisomerase II Inhibitorsantigenotoxicityligninoocytespolyphenolstestes

Identifiers

PMID39127976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.